Trial Profile
Safety and efficacy of rapid infusions of Velaglucerase Alfa in adult with type I Gaucher Disease who had already been treated for at least 3 months with velaglucerase alfa.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology